Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.41 -5.76%

-$0.10 today

Market cap
$99.30M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 4.42M

Average 17.46M

OTLK Interest Expense

Cost of servicing the company's debt during the period.

Outlook Therapeutics, Inc.NASDAQ: OTLK

Interest Expense · Q2 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q2 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $313.51K. Over 3 fiscal years it compounded at -42.5% a year.

Context

  • Interest expense amounted to 20.0% of revenue in FY2025.
  • Interest expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $78.38K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearSep 2025
$283.13K-91.0% YoY
LTMMar 2026
$313.51K— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-91.0%——
3-year CAGR-42.5%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
283.13K USD
Year-over-year change
-91.0%
4-year CAGR
-25.8%

Interest Expense vs competitors

How OTLK compares with its peers on the latest reported figures

  • OTLK's LTM Mar 2026 interest expense of $313.51K is the 5th highest of the 9 companies compared; the peer median is $375.57K.
  • Interest expense amounts to 94.1% of revenue for OTLK, versus a peer median of 30.6%.
OTLK Competitors Peer median
Interest Expense for OTLK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$4.55M -10.3%—21.7%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$904K +6.5%—39.4%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$728K +195.9%-40.2%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$576.15K +115.7%+43.3%40.7%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$313.51K —-42.5%94.1%
CUECue Biopharma, Inc.LTM Mar 2026$175K -74.4%-20.6%0.5%
OSTXOS Therapies IncorporatedLTM Mar 2026$75.34K -93.8%——
IPSCCentury Therapeutics, Inc.LTM Mar 2026$0 ———
EQEquillium, Inc.LTM Mar 2026$0 ———
Peer median (excluding OTLK) $375.57K-1.9%-20.6%30.6%

Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00001.41M
Cost of Revenue262.14K204.69K44.19K113.86K756.33K
Gross Profit(262.14K)(204.69K)(44.19K)(113.86K)657.21K
Gross Margin————46.5%
Research & Development38.96M42.33M26.45M41.76M27.18T
Selling, General & Admin12.77M20.74M26.67M29.94M39.94M
Operating Expenses51.73M62.87M53.13M71.7M67.72M
Depreciation & Amortization262.14K204.69K44.19K113.86K117.05K
EBITDA(51.51M)(64.36M)(57.38M)(72.09M)(63.58M)
EBITDA Margin————-4497.7%
Operating Income(51.73M)(63.07M)(53.13M)(71.7M)(67.06M)
Operating Margin————-4744.3%
Interest Income000906.15K89.74K
Interest Expense936.13K1.49M1.56M3.16M283.13K
Other Income / Expenses(1.43M)(2.98M)(5.85M)(3.66M)3.08M
Income Before Tax(53.16M)(66.05M)(58.98M)(75.36M)(63.98M)
Pre-Tax Margin————-4526.0%
Income Tax Expense2K2.8K2.8K2.8K(1.55M)
Net Income(53.16M)(66.05M)(58.98M)(75.37M)(62.42M)
Net Margin————-4416.2%
EPS (Basic)(6.96)(6.23)(4.72)(4.06)(1.79)
EPS (Diluted)(6.96)(6.23)(4.72)(4.06)(1.79)
Weighted Avg Shares7.63M10.6M12.51M18.55M34.8M
Weighted Avg Shares (Diluted)7.63M10.6M12.51M18.55M25.48M

Outlook Therapeutics, Inc.

NASDAQ:OTLK

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.